Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;25(2):139-147.
doi: 10.1111/ggi.15054. Epub 2025 Jan 3.

Recent advances in biomarkers for senescence: Bridging basic research to clinic

Takeshi Fukumoto  1 , Tatsuo Shimosawa  2 , Mitsutaka Yakabe  3 , Shota Yoshida  4 , Yohko Yoshida  5
Affiliations
Review

Recent advances in biomarkers for senescence: Bridging basic research to clinic

Takeshi Fukumoto et al. Geriatr Gerontol Int. 2025 Feb.

Abstract

In this review, we review the current status of biomarkers for aging and possible perspectives on anti-aging or rejuvenation from the standpoint of biomarkers. Aging is observed in all cells and organs, and we focused on research into senescence in the skin, musculoskeletal system, immune system, and cardiovascular system. Commonly used biomarkers include SA-βgal, cell-cycle markers, senescence-associated secretory phenotype (SASP) factors, damage-associated molecular patterns (DAMPs), and DNA-damage-related markers. In addition, each organ or cell has its specific markers. Generally speaking, a combination of biomarkers is required to define age-related changes. When considering the translation of basic research, biomarkers that are highly sensitive, highly specific, with validation and reliability as well as being non-invasive are optimal; however, currently reported markers do not fulfill the prerequisite for biomarkers. In addition, rodent models of aging do not necessarily represent human aging, and markers in rodent or cell models are not applicable in clinical settings. The prerequisite of clinically applicable biomarkers is that they provide useful information for clinical decision-making, such as predicting disease risk, diagnosing disease, monitoring disease progression, or guiding treatment decisions. Therefore, the development of non-invasive robust, reliable, and useful biomarkers in humans is necessary to develop anti-aging therapy for humans. Geriatr Gerontol Int 2025; 25: 139-147.

Keywords: T cell; epigenetic marker; genetic marker; sarcopenia; ultraviolet.

PubMed Disclaimer

References

    1. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614–636.
    1. Chen W, Kang J, Xia J et al. p53‐related apoptosis resistance and tumor suppression activity in UVB‐induced premature senescent human skin fibroblasts. Int J Mol Med 2008; 21: 645–653.
    1. Dimri GP, Lee X, Basile G et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92: 9363–9367.
    1. Debacq‐Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence‐associated beta‐galactosidase (SA‐betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798–1806.
    1. Martínez‐Zamudio RI, Dewald HK, Vasilopoulos T, Gittens‐Williams L, Fitzgerald‐Bocarsly P, Herbig U. Senescence‐associated β‐galactosidase reveals the abundance of senescent CD8+ T cells in aging humans. Aging Cell 2021; 20: e13344.

LinkOut - more resources